Apoferritin as an ubiquitous nanocarrier with excellent shelf life
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10360756" target="_blank" >RIV/00216208:11130/17:10360756 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11310/17:10360756 RIV/00064203:_____/17:10360756
Výsledek na webu
<a href="http://dx.doi.org/10.2147/IJN.S130267" target="_blank" >http://dx.doi.org/10.2147/IJN.S130267</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/IJN.S130267" target="_blank" >10.2147/IJN.S130267</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Apoferritin as an ubiquitous nanocarrier with excellent shelf life
Popis výsledku v původním jazyce
Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo's ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20 degrees C, 4 degrees C, 20 degrees C, and 37 degrees C in dark, and 4 degrees C and 20 degrees C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20 degrees C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4 degrees C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 mu M of Dox) still retained its ability to inhibit completely the growth of 1.5x10(4) LNCaP cells after 72 hours. ApoDox stored at 20 degrees C and 37 degrees C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4 degrees C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.
Název v anglickém jazyce
Apoferritin as an ubiquitous nanocarrier with excellent shelf life
Popis výsledku anglicky
Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo's ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20 degrees C, 4 degrees C, 20 degrees C, and 37 degrees C in dark, and 4 degrees C and 20 degrees C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20 degrees C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4 degrees C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 mu M of Dox) still retained its ability to inhibit completely the growth of 1.5x10(4) LNCaP cells after 72 hours. ApoDox stored at 20 degrees C and 37 degrees C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4 degrees C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
<a href="/cs/project/GA17-12816S" target="_blank" >GA17-12816S: Konstrukce modifikovaných apoferitinových nanočástic s protinádorovými léčivy a studium mechanismů potencujících jejich efektivitu v terapii</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
International Journal of Nanomedicine [online]
ISSN
1178-2013
e-ISSN
—
Svazek periodika
12
Číslo periodika v rámci svazku
March
Stát vydavatele periodika
NZ - Nový Zéland
Počet stran výsledku
14
Strana od-do
2265-2278
Kód UT WoS článku
000397274500001
EID výsledku v databázi Scopus
2-s2.0-85016330513